Last reviewed · How we verify

BioRay Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

BioRay Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Perjeta Perjeta marketed Receptor tyrosine-protein kinase erbB-2 Oncology
HS627 HS627 phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Tiantan Hospital · 2 shared drug classes
  2. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 2 shared drug classes
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  4. Asan Medical Center · 2 shared drug classes
  5. CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 2 shared drug classes
  6. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
  7. Addpharma Inc. · 2 shared drug classes
  8. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for BioRay Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). BioRay Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioray-pharmaceutical-co-ltd. Accessed 2026-06-10.

Related